Advanced Therapy Medicinal Products (Atmps) Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Advanced Therapy Medicinal Products (Atmps) Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The advanced therapy medicinal products (ATMPs) market is projected to register a CAGR of 13% during the forecast period.

The COVID-19 pandemic has resulted in plummeted revenue generation through approved advanced therapy products designed for non-COVID applications to a manageable extent. This is majorly due to the sudden shift of the global healthcare system toward the management of SARS-CoV-2 infected patients. Nonetheless, the global pandemic has driven the research programs aimed at exploring the application of these therapies in virology research. For instance, in September 2020, ALVR109, an allogeneic T-cell therapy IND application, which is designed for the treatment of patients infected with SARS-CoV-2, received approval from the US Food and Drug Administration (FDA). Similarly, in January 2021, Sorrento Therapeutics Inc. reported positive results from its Phase 1b study of COVI-MSC, a human allogeneic adipose-derived mesenchymal stem cell-based treatment, which is designed for patients suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) or acute respiratory distress (ARD). This broadening application of CAR-T cells in non-oncology applications is certainly expected to benefit the market in terms of revenue growth in the coming years.

Furthermore, a continuous increase in the number of candidates under the global pipeline for advanced therapy is anticipated to bolster the future market revenue. In an analytical article published in Nature Reviews Drug Discovery in June 2021, 2,073 cell therapies in the global pipeline were marked as active, an increase of 572 over the update in 2020 as of April 16, 2021. This is expected to positively impact the market revenue in the coming years.

Moreover, rising competition among the market players to gain substantial market share in the space is anticipated to propel R&D investment flow in the market. For instance, in October 2021, Leucid Bio announced an investment of USD 15.26 million (1 GBP=1.33 USD) for the development of the next generation of innovative CAR-T therapies. Similarly, in June 2021, Blackstone Life Sciences collaborated with Cellex Cell Professionals and Intellia Therapeutics to launch a new CAR-T cell therapy company. These developments are expected to play a vital role in defining market growth.

The estimated large share of the tissue-engineered product is the presence of a relatively large number of commercially approved products under this segment. Furthermore, the increasing application of tissue-engineered products in treatment procedures that require functional restoration of any diseased or injured part of the body is driving the segment growth.

Furthermore, market players continue to undertake various market strategies to boost the adoption of their products. For instance, in January 2021, Vericel Corporation announced the expansion of the medical coverage policy for MACI by United Healthcare. The expansion includes coverage for patients with multiple cartilage defects in the knee and symptomatic full-thickness cartilage defects in the patella. Such initiatives by the company are driving the segment’s growth to a great extent.

A research study was published in the journal Advanced Functional Materials in February 2021 that illustrated the development of hydrogel-based materials that can change shape in response to psychological stimuli. This exhibit great potential as the next generation of materials for bioengineering organs, tissues, and blood vessels or other tubular structures. A constant increase in research programs for the development of innovative tissue-engineered products also supports the segment growth.

North America, with United States at the forefront, is anticipated to account for the major share owing to the presence of strong regulatory framework and funding bodies in the region. For instance, in July 2021, Kriya Therapeutics announced an investment of USD 100 million in a Series B funding round. The objective of the funding is to advance its platform for designing and developing next-generation gene therapies.

Moreover, with the realization of revenue profit through this space in the foreseeable future, market players are making focused attempts including expansion of product and service portfolios to enhance their market presence. For instance, in December 2021, Novartis launched T-Charge as a next-generation CAR-T platform. The platform is designed to serve as the foundation for Novartis’ new investigational CAR-T cell therapies. These developments are anticipated to boost United States market to a great extent in the future market.

The Advanced Therapy Medicinal Products (ATMPs) market is currently fragmented in nature with the presence of several large to small- and medium-sized players. Some of the companies that are currently dominating the market are Novartis AG, Gilead Sciences Inc., JCR Pharmaceuticals Co. Ltd, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Bluebird Bio Inc., UniQure NV, Kolon TissueGene Inc., Vericel Corporation, and PHARMICELL Co. Ltd.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support